Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6891091 | 0.97 | TP53 (0.33) | MBOAT4HTR1AMCHR1TP53HRH3 | |
| SCHEMBL6897336 | 0.96 | TP53 (0.34) | MBOAT4HTR1AMCHR1TP53HRH3 | |
| SCHEMBL6897959 | 0.95 | TP53 (0.36) | MBOAT4MCHR1TP53HRH3 | |
| SCHEMBL6898851 | 0.95 | TP53 (0.36) | MBOAT4MCHR1TP53HRH3 | |
| SCHEMBL6895866 | 0.95 | TP53 (0.34) | MBOAT4HTR1AMCHR1TP53HRH3 | |
| SCHEMBL7657328 | 0.95 | TP53 (0.34) | MBOAT4HTR1AMCHR1TP53HRH3 | |
| SCHEMBL6897826 | 0.95 | TP53 (0.36) | MBOAT4MCHR1TP53HRH3 | |
| SCHEMBL7664089 | 0.94 | TP53 (0.35) | MBOAT4MCHR1TP53 | |
| SCHEMBL6897036 | 0.92 | LMNA (0.36) | MBOAT4MCHR1TP53 | |
| Cadaverine Tartrate SCHEMBL6895714 | 0.91 | TP53 (0.32) | MBOAT4MCHR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | MBOAT4 1816/4885HTR1A 2802/4885MCHR1 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.